211 related articles for article (PubMed ID: 15695296)
21. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
22. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
Moreland LW; Weinblatt ME; Keystone EC; Kremer JM; Martin RW; Schiff MH; Whitmore JB; White BW
J Rheumatol; 2006 May; 33(5):854-61. PubMed ID: 16541481
[TBL] [Abstract][Full Text] [Related]
23. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.
van Vollenhoven RF; Klareskog L
Arthritis Rheum; 2003 Jun; 48(6):1500-3. PubMed ID: 12794816
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
25. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results.
van der Heijde D; Klareskog L; Boers M; Landewé R; Codreanu C; Bolosiu HD; Pedersen R; Fatenejad S;
Ann Rheum Dis; 2005 Nov; 64(11):1582-7. PubMed ID: 15860509
[TBL] [Abstract][Full Text] [Related]
26. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S
Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431
[TBL] [Abstract][Full Text] [Related]
27. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
28. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients.
Martinez A; Salido M; Bonilla G; Pascual-Salcedo D; Fernandez-Arquero M; de Miguel S; Balsa A; de la Concha EG; Fernandez-Gutierrez B
Arthritis Rheum; 2004 Apr; 50(4):1077-82. PubMed ID: 15077289
[TBL] [Abstract][Full Text] [Related]
29. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
Padyukov L; Lampa J; Heimbürger M; Ernestam S; Cederholm T; Lundkvist I; Andersson P; Hermansson Y; Harju A; Klareskog L; Bratt J
Ann Rheum Dis; 2003 Jun; 62(6):526-9. PubMed ID: 12759288
[TBL] [Abstract][Full Text] [Related]
30. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
31. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
32. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
[TBL] [Abstract][Full Text] [Related]
33. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S
Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
35. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
[TBL] [Abstract][Full Text] [Related]
36. Association analysis of single nucleotide polymorphisms of proinflammatory cytokine and their receptors genes with rheumatoid arthritis in northwest Chinese Han population.
You CG; Li XJ; Li YM; Wang LP; Li FF; Guo XL; Gao LN
Cytokine; 2013 Jan; 61(1):133-8. PubMed ID: 23148991
[TBL] [Abstract][Full Text] [Related]
37. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
Wallenius M; Rødevand E; Skomsvoll JF
Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study.
Johnsen AK; Schiff MH; Mease PJ; Moreland LW; Maier AL; Coblyn JS; Helfgott SM; Leff JA; Weinblatt ME
J Rheumatol; 2006 Apr; 33(4):659-64. PubMed ID: 16482646
[TBL] [Abstract][Full Text] [Related]
40. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele.
Reich K; Hüffmeier U; König IR; Lascorz J; Lohmann J; Wendler J; Traupe H; Mössner R; Reis A; Burkhardt H
Arthritis Rheum; 2007 Jun; 56(6):2056-64. PubMed ID: 17530646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
